The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
Table 1
Baseline characteristics of participants.
Variables
ER
PR
HER2
ER−/PR+
Total (n = 198972)
Negative (n = 33335)
Positive (n = 165637)
Total (n = 198972)
Negative (n = 53490)
Positive (n = 145482)
Total (n = 198972)
Negative (n = 168484)
Positive (n = 30488)
Total (n = 198972)
Negative (n = 196890)
Positive (n = 2082)
Site recode (ICD.O.3), n (%)
0.254
0.195
<0.001
0.338
BC
196982 (99.0)
33021 (99.1)
163961 (99)
196982 (99.0)
52929 (99)
144053 (99)
196982 (99.0)
166720 (99)
30262 (99.3)
196982 (99.0)
194916 (99)
2066 (99.2)
BC-LuC
1990 (1.0)
314 (0.9)
1676 (1)
1990 (1.0)
561 (1)
1429 (1)
1990 (1.0)
1764 (1)
226 (0.7)
1990 (1.0)
1974 (1)
16 (0.8)
Age, n (%)
<0.001
<0.001
<0.001
<0.001
≤40
11337 (5.7)
3252 (9.8)
8085 (4.9)
11337 (5.7)
4267 (8)
7070 (4.9)
11337 (5.7)
8403 (5)
2934 (9.6)
11337 (5.7)
11120 (5.6)
217 (10.4)
40–60
85657 (43.0)
16063 (48.2)
69594 (42)
85657 (43.0)
23738 (44.4)
61919 (42.6)
85657 (43.0)
70372 (41.8)
15285 (50.1)
85657 (43.0)
84617 (43)
1040 (50)
≥60
101978 (51.3)
14020 (42.1)
87958 (53.1)
101978 (51.3)
25485 (47.6)
76493 (52.6)
101978 (51.3)
89709 (53.2)
12269 (40.2)
101978 (51.3)
101153 (51.4)
825 (39.6)
Sex, n (%)
<0.001
<0.001
0.016
0.002
Male
1338 (0.7)
38 (0.1)
1300 (0.8)
1338 (0.7)
118 (0.2)
1220 (0.8)
1338 (0.7)
1165 (0.7)
173 (0.6)
1338 (0.7)
1336 (0.7)
2 (0.1)
Female
197634 (99.3)
33297 (99.9)
164337 (99.2)
197634 (99.3)
53372 (99.8)
144262 (99.2)
197634 (99.3)
167319 (99.3)
30315 (99.4)
197634 (99.3)
195554 (99.3)
2080 (99.9)
Race, n (%)
<0.001
<0.001
<0.001
<0.001
American Indian/Alaska native
1217 (0.6)
211 (0.6)
1006 (0.6)
1217 (0.6)
318 (0.6)
899 (0.6)
1217 (0.6)
991 (0.6)
226 (0.7)
1217 (0.6)
1198 (0.6)
19 (0.9)
Asian or Pacific Islander
18801 (9.4)
3062 (9.2)
15739 (9.5)
18801 (9.4)
4969 (9.3)
13832 (9.5)
18801 (9.4)
15244 (9)
3557 (11.7)
18801 (9.4)
18616 (9.5)
185 (8.9)
Black
20734 (10.4)
5851 (17.6)
14883 (9)
20734 (10.4)
8407 (15.7)
12327 (8.5)
20734 (10.4)
17070 (10.1)
3664 (12)
20734 (10.4)
20392 (10.4)
342 (16.4)
White
158220 (79.5)
24211 (72.6)
134009 (80.9)
158220 (79.5)
39796 (74.4)
118424 (81.4)
158220 (79.5)
135179 (80.2)
23041 (75.6)
158220 (79.5)
156684 (79.6)
1536 (73.8)
Marital status, n (%)
<0.001
<0.001
<0.001
0.017
Married
117748 (59.2)
19308 (57.9)
98440 (59.4)
117748 (59.2)
30739 (57.5)
87009 (59.8)
117748 (59.2)
99437 (59)
18311 (60.1)
117748 (59.2)
116518 (59.2)
1230 (59.1)
Single
30858 (15.5)
5882 (17.6)
24976 (15.1)
30858 (15.5)
9047 (16.9)
21811 (15)
30858 (15.5)
25530 (15.2)
5328 (17.5)
30858 (15.5)
30494 (15.5)
364 (17.5)
Divorced and separated
24532 (12.3)
4291 (12.9)
20241 (12.2)
24532 (12.3)
6863 (12.8)
17669 (12.1)
24532 (12.3)
20806 (12.3)
3726 (12.2)
24532 (12.3)
24278 (12.3)
254 (12.2)
Widowed
25834 (13.0)
3854 (11.6)
21980 (13.3)
25834 (13.0)
6841 (12.8)
18993 (13.1)
25834 (13.0)
22711 (13.5)
3123 (10.2)
25834 (13.0)
25600 (13)
234 (11.2)
Months from diagnosis to treatment, n (%)
<0.001
<0.001
<0.001
0.028
≤1 month
150419 (75.6)
26222 (78.7)
124197 (75)
150419 (75.6)
41654 (77.9)
108765 (74.8)
150419 (75.6)
127063 (75.4)
23356 (76.6)
150419 (75.6)
148793 (75.6)
1626 (78.1)
1–3 months
44374 (22.3)
6443 (19.3)
37931 (22.9)
44374 (22.3)
10709 (20)
33665 (23.1)
44374 (22.3)
37894 (22.5)
6480 (21.3)
44374 (22.3)
43957 (22.3)
417 (20)
>3 months
4179 (2.1)
670 (2)
3509 (2.1)
4179 (2.1)
1127 (2.1)
3052 (2.1)
4179 (2.1)
3527 (2.1)
652 (2.1)
4179 (2.1)
4140 (2.1)
39 (1.9)
CS tumor size, n (%)
<0.001
<0.001
<0.001
<0.001
≤2 cm
110122 (55.3)
12834 (38.5)
97288 (58.7)
110122 (55.3)
22907 (42.8)
87215 (59.9)
110122 (55.3)
97003 (57.6)
13119 (43)
110122 (55.3)
109346 (55.5)
776 (37.3)
2–5 cm
70660 (35.5)
15520 (46.6)
55140 (33.3)
70660 (35.5)
23168 (43.3)
47492 (32.6)
70660 (35.5)
57443 (34.1)
13217 (43.4)
70660 (35.5)
69635 (35.4)
1025 (49.2)
>5 cm
18190 (9.1)
4981 (14.9)
13209 (8)
18190 (9.1)
7415 (13.9)
10775 (7.4)
18190 (9.1)
14038 (8.3)
4152 (13.6)
18190 (9.1)
17909 (9.1)
281 (13.5)
Laterality, n (%)
0.126
0.004
0.002
0.108
Left
101188 (50.9)
17122 (51.4)
84066 (50.8)
101188 (50.9)
27530 (51.5)
73658 (50.6)
101188 (50.9)
85477 (50.7)
15711 (51.5)
101188 (50.9)
100157 (50.9)
1031 (49.5)
Right
97759 (49.1)
16209 (48.6)
81550 (49.2)
97759 (49.1)
25953 (48.5)
71806 (49.4)
97759 (49.1)
82990 (49.3)
14769 (48.4)
97759 (49.1)
96709 (49.1)
1050 (50.4)
Bilateral
25 (0.0)
4 (0)
21 (0)
25 (0.0)
7 (0)
18 (0)
25 (0.0)
17 (0)
8 (0)
25 (0.0)
24 (0)
1 (0)
Combined summary stage, n (%)
<0.001
<0.001
<0.001
<0.001
Distant
8249 (4.1)
2091 (6.3)
6158 (3.7)
8249 (4.1)
3298 (6.2)
4951 (3.4)
8249 (4.1)
6028 (3.6)
2221 (7.3)
8249 (4.1)
8119 (4.1)
130 (6.2)
Localized
129366 (65.0)
19351 (58.1)
110015 (66.4)
129366 (65.0)
31682 (59.2)
97684 (67.1)
129366 (65.0)
112971 (67.1)
16395 (53.8)
129366 (65.0)
128148 (65.1)
1218 (58.5)
Regional
61357 (30.8)
11893 (35.7)
49464 (29.9)
61357 (30.8)
18510 (34.6)
42847 (29.5)
61357 (30.8)
49485 (29.4)
11872 (38.9)
61357 (30.8)
60623 (30.8)
734 (35.3)
AJCC (7th), n (%)
<0.001
<0.001
<0.001
<0.001
I
100449 (50.5)
11383 (34.1)
89066 (53.8)
100449 (50.5)
20480 (38.3)
79969 (55)
100449 (50.5)
89243 (53)
11206 (36.8)
100449 (50.5)
99758 (50.7)
691 (33.2)
II
68478 (34.4)
14611 (43.8)
53867 (32.5)
68478 (34.4)
21714 (40.6)
46764 (32.1)
68478 (34.4)
56275 (33.4)
12203 (40)
68478 (34.4)
67505 (34.3)
973 (46.7)
III
22143 (11.1)
5409 (16.2)
16734 (10.1)
22143 (11.1)
8218 (15.4)
13925 (9.6)
22143 (11.1)
17150 (10.2)
4993 (16.4)
22143 (11.1)
21848 (11.1)
295 (14.2)
IV
7902 (4.0)
1932 (5.8)
5970 (3.6)
7902 (4.0)
3078 (5.8)
4824 (3.3)
7902 (4.0)
5816 (3.5)
2086 (6.8)
7902 (4.0)
7779 (4)
123 (5.9)
Radiation, n (%)
<0.001
<0.001
<0.001
<0.001
Without
86484 (43.5)
16061 (48.2)
70423 (42.5)
86484 (43.5)
25168 (47.1)
61316 (42.1)
86484 (43.5)
71351 (42.3)
15133 (49.6)
86484 (43.5)
85499 (43.4)
985 (47.3)
With
112488 (56.5)
17274 (51.8)
95214 (57.5)
112488 (56.5)
28322 (52.9)
84166 (57.9)
112488 (56.5)
97133 (57.7)
15355 (50.4)
112488 (56.5)
111391 (56.6)
1097 (52.7)
Chemotherapy, n (%)
<0.001
<0.001
<0.001
<0.001
Without
113170 (56.9)
7292 (21.9)
105878 (63.9)
113170 (56.9)
17163 (32.1)
96007 (66)
113170 (56.9)
106248 (63.1)
6922 (22.7)
113170 (56.9)
112673 (57.2)
497 (23.9)
With
85802 (43.1)
26043 (78.1)
59759 (36.1)
85802 (43.1)
36327 (67.9)
49475 (34)
85802 (43.1)
62236 (36.9)
23566 (77.3)
85802 (43.1)
84217 (42.8)
1585 (76.1)
Disease-specific death, n (%)
<0.001
<0.001
<0.001
<0.001
Alive
179397 (90.2)
26783 (80.3)
152614 (92.1)
179397 (90.2)
44141 (82.5)
135256 (93)
179397 (90.2)
152477 (90.5)
26920 (88.3)
179397 (90.2)
177724 (90.3)
1673 (80.4)
Death
19575 (9.8)
6552 (19.7)
13023 (7.9)
19575 (9.8)
9349 (17.5)
10226 (7)
19575 (9.8)
16007 (9.5)
3568 (11.7)
19575 (9.8)
19166 (9.7)
409 (19.6)
Survival months (mean ± SD)
71.8 ± 27.6
66.1 ± 31.4
73.0 ± 26.7
<0.001
71.8 ± 27.6
67.5 ± 30.6
73.4 ± 26.3
<0.001
71.8 ± 27.6
72.1 ± 27.6
70.5 ± 28.1
<0.001
71.8 ± 27.6
71.9 ± 27.6
66.7 ± 31.0
<0.001
All-cause death, n (%)
<0.001
<0.001
0.652
<0.001
Alive
164475 (82.7)
24551 (73.6)
139924 (84.5)
164475 (82.7)
40176 (75.1)
124299 (85.4)
164475 (82.7)
139245 (82.6)
25230 (82.8)
164475 (82.7)
162922 (82.7)
1553 (74.6)
Death
34497 (17.3)
8784 (26.4)
25713 (15.5)
34497 (17.3)
13314 (24.9)
21183 (14.6)
34497 (17.3)
29239 (17.4)
5258 (17.2)
34497 (17.3)
33968 (17.3)
529 (25.4)
Bone metastasis, n (%)
0.265
<0.001
<0.001
0.853
Without
193730 (97.4)
32487 (97.5)
161243 (97.3)
193730 (97.4)
51865 (97)
141865 (97.5)
193730 (97.4)
164456 (97.6)
29274 (96)
193730 (97.4)
191701 (97.4)
2029 (97.5)
With
5242 (2.6)
848 (2.5)
4394 (2.7)
5242 (2.6)
1625 (3)
3617 (2.5)
5242 (2.6)
4028 (2.4)
1214 (4)
5242 (2.6)
5189 (2.6)
53 (2.5)
Brain metastasis, n (%)
<0.001
<0.001
<0.001
0.282
Without
198408 (99.7)
33129 (99.4)
165279 (99.8)
198408 (99.7)
53184 (99.4)
145224 (99.8)
198408 (99.7)
168091 (99.8)
30317 (99.4)
198408 (99.7)
196335 (99.7)
2073 (99.6)
With
564 (0.3)
206 (0.6)
358 (0.2)
564 (0.3)
306 (0.6)
258 (0.2)
564 (0.3)
393 (0.2)
171 (0.6)
564 (0.3)
555 (0.3)
9 (0.4)
Liver metastasis, n (%)
<0.001
<0.001
<0.001
<0.001
Without
196984 (99.0)
32668 (98)
164316 (99.2)
196984 (99.0)
52524 (98.2)
144460 (99.3)
196984 (99.0)
167307 (99.3)
29677 (97.3)
196984 (99.0)
194950 (99)
2034 (97.7)
With
1988 (1.0)
667 (2)
1321 (0.8)
1988 (1.0)
966 (1.8)
1022 (0.7)
1988 (1.0)
1177 (0.7)
811 (2.7)
1988 (1.0)
1940 (1)
48 (2.3)
Lung metastasis, n (%)
<0.001
<0.001
<0.001
<0.001
Without
196625 (98.8)
32585 (97.8)
164040 (99)
196625 (98.8)
52444 (98)
144181 (99.1)
196625 (98.8)
166805 (99)
29820 (97.8)
196625 (98.8)
194596 (98.8)
2029 (97.5)
With
2347 (1.2)
750 (2.2)
1597 (1)
2347 (1.2)
1046 (2)
1301 (0.9)
2347 (1.2)
1679 (1)
668 (2.2)
2347 (1.2)
2294 (1.2)
53 (2.5)
Note. BC-LuC: breast cancer with primary lung cancer; BC: breast cancer; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2. value <0.05 was considered statistically significant.
